HUM250103P260000
- 0.05
- 0.000.00%
Humana Newsroom
Humana Analyst Ratings
Piper Sandler Maintains Humana(HUM.US) With Hold Rating, Maintains Target Price $288
Bernstein Maintains Humana(HUM.US) With Buy Rating, Raises Target Price to $322
Bernstein Remains a Buy on Humana (HUM)
Piper Sandler Maintains Humana(HUM.US) With Hold Rating, Raises Target Price to $288
Truist Financial Maintains Humana(HUM.US) With Hold Rating, Announces Target Price $290
Humana Analyst Ratings
Baird Maintains Humana(HUM.US) With Hold Rating, Cuts Target Price to $270
Baird Adjusts Humana Price Target to $270 From $374, Maintains Neutral Rating
Humana Is Maintained at Equal-Weight by Morgan Stanley
Humana Analyst Ratings
Morgan Stanley Adjusts Price Target on Humana to $301 From $288
Morgan Stanley Maintains Humana(HUM.US) With Hold Rating, Raises Target Price to $301
Morgan Stanley Sticks to Their Hold Rating for Humana (HUM)
Piper Sandler Maintains Humana(HUM.US) With Hold Rating, Cuts Target Price to $270
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Alcon (ALC) and Humana (HUM)
Nephron Initiates Humana(HUM.US) With Hold Rating, Announces Target Price $294
Nephron Research Downgrades Humana to Hold From Buy, $294 Price Target
Stephen Baxter's Buy Rating Driven by Strategic CFO Appointment and Positive EPS Outlook for Humana
Cautious Hold Rating on Humana Amid Transition and Uncertainty